Two important new developments may mean that many more researchers will soon be able to access and analyze data from many more clinical trials. In recent years, in response to troubling and far-reaching questions about the availability and reliability of clinical trial data, reformers have called for new policies that would require drug companies and other clinical trial sponsors to provide outside researchers access to the data. The two announcements today appear to bring the open data movement closer to the tipping point.
Hey, check out all the research scientist jobs. Post your resume today!
